NASDAQ:QURE - uniQure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.95
  • Forecasted Upside: 62.87 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.01 (0.03%)

This chart shows the closing price for QURE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New uniQure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QURE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QURE

Analyst Price Target is $59.95
▲ +62.87% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for uniQure in the last 3 months. The average price target is $59.95, with a high forecast of $95.00 and a low forecast of $27.46. The average price target represents a 62.87% upside from the last price of $36.81.

This chart shows the closing price for QURE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in uniQure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021SVB LeerinkReiterated RatingBuyMedium
7/27/2021Credit Suisse GroupReiterated RatingOutperform$78.00 ➝ $27.46High
7/27/2021Chardan CapitalReiterated RatingBuy$100.00 ➝ $95.00High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
6/14/2021BTIG ResearchInitiated CoverageBuy$46.00High
5/31/2021SVB LeerinkReiterated RatingBuyLow
5/20/2021UBS GroupInitiated CoverageNeutral$40.00Medium
5/19/2021HC WainwrightBoost Price TargetBuy$80.00 ➝ $90.00Medium
4/1/2021MizuhoUpgradeNeutral ➝ Buy$52.00High
3/2/2021Chardan CapitalBoost Price TargetBuy$85.00 ➝ $100.00High
1/7/2021GuggenheimUpgradeNeutral ➝ Buy$62.00N/A
12/22/2020Royal Bank of CanadaBoost Price TargetHold ➝ Outperform$53.00 ➝ $61.00Medium
12/21/2020HC WainwrightBoost Price TargetHold ➝ Buy$80.00 ➝ $85.00High
12/9/2020Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$55.00 ➝ $62.00Low
12/9/2020MizuhoBoost Price TargetNeutral$46.00 ➝ $52.00Low
11/24/2020HC WainwrightInitiated CoverageBuy$80.00Low
11/20/2020Credit Suisse GroupBoost Price TargetOutperform$76.00 ➝ $78.00High
11/11/2020Berenberg BankInitiated CoverageBuy$59.00High
11/9/2020Jefferies Financial GroupInitiated CoverageBuy$55.00Medium
11/4/2020Cantor FitzgeraldInitiated CoverageOverweight$65.00High
10/28/2020MizuhoLower Price TargetNeutral$61.00 ➝ $46.00High
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$61.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$75.00High
8/11/2020Chardan CapitalReiterated RatingBuy$80.00Medium
7/31/2020Credit Suisse GroupReiterated RatingBuy$76.00Low
7/31/2020Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $57.00Medium
7/14/2020MizuhoReiterated RatingHold$61.00Medium
6/25/2020Chardan CapitalLower Price TargetBuy$105.00 ➝ $80.00High
6/25/2020HC WainwrightLower Price TargetBuy$73.00 ➝ $64.00High
6/25/2020Stifel NicolausLower Price TargetBuy$86.00 ➝ $78.00High
6/25/2020MizuhoReiterated RatingBuy ➝ Neutral$90.00 ➝ $61.00High
6/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $56.00High
6/25/2020Robert W. BairdDowngradeOutperform ➝ Neutral$58.00High
6/19/2020HC WainwrightReiterated RatingBuy$73.00Low
5/29/2020Chardan CapitalReiterated RatingBuy$105.00Medium
5/8/2020Chardan CapitalReiterated RatingBuy$105.00Low
4/30/2020MizuhoReiterated RatingBuy$90.00Low
3/3/2020HC WainwrightReiterated RatingBuy$73.00Medium
3/3/2020Chardan CapitalLower Price TargetBuy$125.00 ➝ $105.00High
2/10/2020HC WainwrightReiterated RatingBuy$73.00Low
1/29/2020Chardan CapitalReiterated RatingBuy$125.00Low
1/23/2020Cantor FitzgeraldBoost Price TargetOverweight$94.00 ➝ $96.00Low
12/23/2019HC WainwrightReiterated RatingBuy$73.00N/A
12/20/2019SunTrust BanksInitiated CoverageBuy$90.00Medium
12/10/2019MizuhoReiterated RatingBuy$67.00 ➝ $90.00Medium
12/9/2019HC WainwrightReiterated RatingBuy$73.00Low
12/9/2019Chardan CapitalReiterated RatingBuy$125.00Medium
12/3/2019Piper Jaffray CompaniesReiterated RatingBuy$80.00Medium
12/3/2019CowenInitiated CoverageOutperformHigh
12/3/2019The Goldman Sachs GroupInitiated CoverageBuy$98.00High
11/5/2019Credit Suisse GroupInitiated CoverageOutperform$76.00High
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
10/14/2019HC WainwrightReiterated RatingBuy$73.00Medium
10/11/2019Stifel NicolausInitiated CoverageBuy$79.00Medium
9/24/2019Sanford C. BernsteinInitiated CoverageOutperform$73.00High
9/12/2019MizuhoInitiated CoverageBuy$67.00Low
9/3/2019HC WainwrightReiterated RatingBuyMedium
9/3/2019Chardan CapitalReiterated RatingBuyMedium
7/29/2019GuggenheimDowngradeBuy ➝ NeutralMedium
7/8/2019HC WainwrightSet Price TargetBuy$73.00Low
7/8/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$81.00 ➝ $94.00High
6/11/2019Janney Montgomery ScottReiterated RatingBuyHigh
5/10/2019Cantor FitzgeraldSet Price TargetBuy$81.00High
5/7/2019SunTrust BanksBoost Price TargetBuy$76.00High
4/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
3/28/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$85.00Low
3/15/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $90.00Low
3/7/2019Cantor FitzgeraldReiterated RatingBuy$81.00Medium
3/4/2019Chardan CapitalBoost Price TargetBuy$70.00 ➝ $100.00Low
2/28/2019Wells Fargo & CompanyBoost Price TargetOutperform$51.00 ➝ $65.00Low
2/26/2019HC WainwrightReiterated RatingBuyHigh
2/26/2019SunTrust BanksBoost Price TargetBuy ➝ Positive$64.00High
2/25/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$68.00 ➝ $81.00High
2/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $73.00High
2/8/2019Cantor FitzgeraldReiterated RatingBuy$68.00Medium
1/14/2019HC WainwrightSet Price TargetBuy$60.00Medium
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$72.00 ➝ $72.00High
12/17/2018GuggenheimInitiated CoverageBuy$35.00Low
12/4/2018HC WainwrightSet Price TargetBuy$60.00High
12/3/2018Chardan CapitalReiterated RatingBuy$70.00Medium
11/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $60.00Medium
11/16/2018B. RileyBoost Price TargetBuy ➝ Buy$50.00 ➝ $72.00Medium
11/15/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
11/15/2018HC WainwrightSet Price TargetBuy$48.00High
11/15/2018SVB LeerinkBoost Price TargetOutperform ➝ Positive$61.00 ➝ $76.00High
11/7/2018Chardan CapitalBoost Price TargetBuy$50.00 ➝ $70.00Low
11/7/2018HC WainwrightSet Price TargetBuy$48.00High
10/19/2018HC WainwrightSet Price TargetBuy$48.00High
10/18/2018Chardan CapitalReiterated RatingBuy$50.00High
10/11/2018HC WainwrightSet Price TargetBuy$48.00Low
10/3/2018Cantor FitzgeraldSet Price TargetBuy$58.00High
9/24/2018HC WainwrightBoost Price TargetBuy ➝ Buy$42.00 ➝ $48.00High
8/23/2018HC WainwrightSet Price TargetBuy$42.00Low
8/23/2018Cantor FitzgeraldSet Price TargetBuy$58.00Low
8/13/2018CowenReiterated RatingBuyMedium
8/11/2018Cantor FitzgeraldSet Price TargetBuy$58.00Low
8/9/2018HC WainwrightSet Price TargetBuy$42.00High
8/8/2018Janney Montgomery ScottReiterated RatingBuyLow
7/26/2018Cantor FitzgeraldInitiated CoverageOverweight$58.00High
7/17/2018HC WainwrightSet Price TargetBuy$42.00High
6/29/2018HC WainwrightSet Price TargetBuy$42.00Medium
6/27/2018B. RileyInitiated CoverageBuy$50.00High
5/24/2018SunTrust BanksInitiated CoverageBuy$48.00High
5/22/2018HC WainwrightReiterated RatingBuy$42.00High
5/16/2018Wells Fargo & CompanyInitiated CoverageOutperform$47.00Medium
5/7/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$26.00 ➝ $63.00Low
5/1/2018HC WainwrightSet Price TargetBuy$35.00Medium
4/30/2018Chardan CapitalReiterated RatingBuyHigh
4/23/2018HC WainwrightSet Price TargetBuy$35.00High
3/20/2018Janney Montgomery ScottReiterated RatingBuy$30.00High
3/15/2018HC WainwrightSet Price TargetBuy$35.00High
2/20/2018HC WainwrightSet Price TargetBuy$35.00Low
1/3/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$25.00Low
12/7/2017HC WainwrightSet Price TargetBuy$28.00High
12/1/2017HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
11/24/2017OppenheimerReiterated RatingHoldLow
11/7/2017SVB LeerinkBoost Price Target$19.00 ➝ $26.00N/A
11/7/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$22.00N/A
10/20/2017SVB LeerinkBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $19.00N/A
7/23/2017Chardan CapitalSet Price TargetBuy$13.00High
6/30/2017OppenheimerReiterated RatingOutperform$17.00Low
5/24/2017CowenReiterated RatingBuyMedium
5/16/2017OppenheimerSet Price TargetBuy$17.00Medium
4/12/2017Jefferies Financial GroupReiterated RatingHold$8.00Low
3/22/2017OppenheimerReiterated RatingBuyLow
1/30/2017Chardan CapitalReiterated RatingPositive$12.00N/A
12/25/2016OppenheimerSet Price TargetBuy$17.00N/A
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 ➝ $15.00N/A
12/2/2016SVB LeerinkReiterated RatingOutperformN/A
11/28/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $8.00N/A
11/21/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $8.00N/A
11/15/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
11/15/2016Chardan CapitalReiterated RatingBuy$20.00 ➝ $12.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 34 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 10 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 10 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
uniQure logo
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $36.81
Low: $36.30
High: $37.30

50 Day Range

MA: $29.88
Low: $26.01
High: $36.81

52 Week Range

Now: $36.81
Low: $25.80
High: $52.19


7,709,666 shs

Average Volume

491,884 shs

Market Capitalization

$1.70 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of uniQure?

The following equities research analysts have issued research reports on uniQure in the last twelve months: Berenberg Bank, BTIG Research, Cantor Fitzgerald, Chardan Capital, Credit Suisse Group AG, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Royal Bank of Canada, SVB Leerink LLC, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for QURE.

What is the current price target for uniQure?

11 Wall Street analysts have set twelve-month price targets for uniQure in the last year. Their average twelve-month price target is $59.95, suggesting a possible upside of 62.9%. Chardan Capital has the highest price target set, predicting QURE will reach $95.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $27.46 for uniQure in the next year.
View the latest price targets for QURE.

What is the current consensus analyst rating for uniQure?

uniQure currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QURE will outperform the market and that investors should add to their positions of uniQure.
View the latest ratings for QURE.

What other companies compete with uniQure?

How do I contact uniQure's investor relations team?

uniQure's physical mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company's listed phone number is (120) 240-6000 and its investor relations email address is [email protected] The official website for uniQure is